High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: Mechanisms and a phase I/IIa study

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Polireddy, Kishore ^a,b   Dong, Ruochen ^a,b   Reed, Gregory ^a   Yu, Jun ^a,b   Chen, Ping ^a,b   Williamson, Stephen ^a   Violet, Pierre Christian ^c   Pessetto, Ziyan ^a   Godwin, Andrew K ^a   Fan, Fang ^a   Levine, Mark ^c   Drisko, Jeanne A ^b   Chen, Qi ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; DEOXYCYTIDINE; GEMCITABINE;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; METASTASIS; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PARENTERAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ASCORBIC ACID; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85038104814     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-17568-8     Document Type: Article

References (63)

1. American Cancer Society. Cancer Facts and Figures 2017 (2017).
2. Burris, H. III et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15, 2403 (1997).
3. Renouf, D. & Moore, M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 10, 529-540, https://doi.org/10.1586/era.10.21 (2010).
4. Kim, R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 12, 8-9, https://doi.org/10.1016/S1470-2045(10)70237-0 (2011).
5. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691-1703, https://doi.org/10.1056/NEJMoa1304369 (2013).
6. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966, https://doi.org/10.1200/JCO.2006.07.9525 (2007).
7. Dahan, L. et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59, 1527-1534, https://doi.org/10.1136/gut.2010.216135 (2010).
8. Oberstein, P. E. & Saif, M. W. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP 12, 96-100 (2011).
9. Ma, Y. et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science translational medicine. 6, 222ra218, https://doi.org/10.1126/scitranslmed.3007154 (2014).
10. Hoffer, L. J. et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19, 1969-1974, https://doi.org/10.1093/annonc/mdn377 (2008).
11. Monti, D. A. et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7, e29794, https://doi.org/10.1371/journal.pone.0029794 (2012).
12. Welsh, J. L. et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71, 765-775, https://doi.org/10.1007/s00280-013-2070-8 (2013).
13. Schoenfeld, J. D. et al. O2-and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell, https://doi.org/10.1016/j.ccell.2017.02.018 (2017).
14. Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391-1396, https://doi.org/10.1126/science.aaa5004 (2015).
15. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806, https://doi.org/10.1126/science.1164368 (2008).
16. Graumlich, J. F. et al. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14, 1133-1139 (1997).
17. Levine, M. et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93, 3704-3709 (1996).
18. Padayatty, S. J. et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140, 533-537 (2004).
19. Chen, Q. et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105, 11105-11109, https://doi.org/10.1073/pnas.0804226105 (2008).
20. Chen, Q. et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104, 8749-8754, https://doi.org/10.1073/pnas.0702854104 (2007).
21. Chen, Q. et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102, 13604-13609, https://doi.org/10.1073/pnas.0506390102 (2005).
22. Parrow, N. L., Leshin, J. A. & Levine, M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal 19, 2141-2156, https://doi.org/10.1089/ars.2013.5372 (2013).
23. Du, J. et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16, 509-520, https://doi.org/10.1158/1078-0432.CCR-09-1713 (2010).
24. Verrax, J. & Calderon, P. B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47, 32-40, https://doi.org/10.1016/j.freeradbiomed.2009.02.016 (2009).
25. Pollard, H. B., and Levine, M. A., Eidelman, O. & Pollard, M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24, 249-255 (2010).
26. Takemura, Y. et al. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394, 249-253, https://doi.org/10.1016/j.bbrc.2010.02.012 (2010).
27. Deubzer, B. et al. H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem 25, 767-774, https://doi.org/10.1159/000315098 (2010).
28. Espey, M. G. et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50, 1610-1619, https://doi.org/10.1016/j.freeradbiomed.2011.03.007 (2011).
29. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361, https://doi.org/10.1016/j.cell.2011.11.025 (2012).
30. Ellenrieder, V. et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 85, 14-20, https://doi.org/10.1002/(SICI)1097-0215 (2000).
31. Chiarugi, A. & Moskowitz, M. A. Cell biology. PARP-1-a perpetrator of apoptotic cell death? Science 297, 200-201, https://doi.org/10.1126/science.1074592 (2002).
32. Pero, R. W. et al. Oxidative stress induces DNA damage and inhibits the repair of DNA lesions induced by N-acetoxy-2-acetylaminofluorene in human peripheral mononuclear leukocytes. Cancer Res 50, 4619-4625 (1990).
33. Warburg, O., Wind, F. & Negelein, E. The Metabolism of Tumors in the Body. J Gen Physiol 8, 519-530 (1927).
34. Sauve, A. A. & Youn, D. Y. Sirtuins: NAD(+)-dependent deacetylase mechanism and regulation. Current opinion in chemical biology 16, 535-543, https://doi.org/10.1016/j.cbpa.2012.10.003 (2012).
35. Perdiz, D., Mackeh, R., Pous, C. & Baillet, A. The ins and outs of tubulin acetylation: more than just a post-translational modification? Cellular signalling 23, 763-771, https://doi.org/10.1016/j.cellsig.2010.10.014 (2011).
36. Hammond, J. W., Cai, D. & Verhey, K. J. Tubulin modifications and their cellular functions. Current opinion in cell biology 20, 71-76, https://doi.org/10.1016/j.ceb.2007.11.010 (2008).
37. Kirkland, W. L. & Burton, P. R. Cyclic adenosine monophosphate-mediated stabilization of mouse neuroblastoma cell neuritis microtubules exposed to low temperature. Nat New Biol 240, 205-207 (1972).
38. Marangon, E. et al. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. J Mass Spectrom 43, 216-223, https://doi.org/10.1002/jms.1293 (2008).
39. Doskey, C. M. et al. Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy. Redox biology 10, 274-284, https://doi.org/10.1016/j.redox.2016.10.010 (2016).
40. Du, J., and Wagner, B. A., Buettner, G. R. & Cullen, J. J. Role of labile iron in the toxicity of pharmacological ascorbate. Free Radic Biol Med 84, 289-295, https://doi.org/10.1016/j.freeradbiomed.2015.03.033 (2015).
41. Venturelli, S. et al. Epigenetic impacts of ascorbate on human metastatic melanoma cells. Frontiers in oncology 4, 227, https://doi.org/10.3389/fonc.2014.00227 (2014).
42. Castro, M. L., McConnell, M. J. & Herst, P. M. Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specific. Free Radic Biol Med 74, 200-209, https://doi.org/10.1016/j.freeradbiomed.2014.06.022 (2014).
43. Levine, M. & Violet, P. C. Data Triumph at C. Cancer Cell 31, 467-469, https://doi.org/10.1016/j.ccell.2017.03.008 (2017).
44. Sinnberg, T. et al. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines. J Cell Mol Med 18, 530-541, https://doi.org/10.1111/jcmm.12207 (2014).
45. Kim, J. et al. Enhanced antitumor activity of vitamin C via p53 in cancer cells. Free Radic Biol Med 53, 1607-1615, https://doi.org/10.1016/j.freeradbiomed.2012.07.079 (2012).
46. Hong, S. W. et al. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32, 1508-1517, https://doi.org/10.1038/onc.2012.176 (2013).
47. Ma, E. et al. Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. Free Radic Biol Med 113, 36-47, https://doi.org/10.1016/j.freeradbiomed.2017.09.008 (2017).
48. Xu, R. H. et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65, 613-621 (2005).
49. ∗-and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280, 4254-4263, https://doi.org/10.1074/jbc.M411662200 (2005).
50. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563, https://doi.org/10.1038/nature06188 (2007).
51. Merika, E. E., Syrigos, K. N. & Saif, M. W. Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012, 781765, https://doi.org/10.1155/2012/781765 (2012).
52. Bissell, M. J. & Radisky, D. Putting tumours in context. Nat Rev Cancer 1, 46-54, https://doi.org/10.1038/35094059 (2001).
53. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315, 1650-1659, https://doi.org/10.1056/NEJM198612253152606 (1986).
54. Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734, https://doi.org/10.1016/j.ccr.2014.04.005 (2014).
55. Chen, Q., Polireddy, K., Chen, P. & Dong, R. The unpaved journey of vitamin C in cancer treatment. Can J Physiol Pharmacol 93, 1055-1063, https://doi.org/10.1139/cjpp-2014-0509 (2015).
56. Zhang, D. S. et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 71, 1065-1072, https://doi.org/10.1007/s00280-013-2102-4 (2013).
57. Goldstein, D. et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107, https://doi.org/10.1093/jnci/dju413 (2015).
58. Chiorean, E. G. et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 27, 654-660, https://doi.org/10.1093/annonc/mdw006 (2016).
59. Ueno, H. et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77, 595-603, https://doi.org/10.1007/s00280-016-2972-3 (2016).
60. Eisenhauer, E. et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45, 288-247 (2009).
61. Chen, Q., Polireddy, K., Chen, P. & Dong, R. The unpaved journey of vitamin C in cancer treatment. Can J Physiol Pharmacol 93, 1-9 (2015).
62. Ma, Y. et al. A Convenient Method for Measuring Blood Ascorbate Concentrations in Patients Receiving High-Dose Intravenous Ascorbate. Journal of the American College of Nutrition 32, 187-193, https://doi.org/10.1080/07315724.2013.791167 (2013).
63. Bollu, L. R. et al. Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Cell cycle 13, 2415-2430, https://doi.org/10.4161/cc.29338 (2014).